17P KBA1413: An antibody derived from a cured AML patient, recognizes a unique glycoepitope shared by AML, MDS and several solid cancer cells
The use of human B cells for antigen- and antibody discovery is on the rise due to the emergence of new techniques to tap into the human antigen-experienced B cell repertoire. To identify new targets for immunotherapy, we screened the B-cell repertoire of a patient with high-risk acute myeloid leukemia (AML) who mounted a potent graft versus leukemia immune response following allogeneic stem cell transplantation.
Authors
- Remko Schotte
- Martijn Kedde (ORCID: https://orcid.org/0009-0005-0654-3246)
- Bradley R. Pieters (ORCID: https://orcid.org/0000-0002-7427-8836)
- Vanessa Clerico Mosina (ORCID: https://orcid.org/0000-0001-8013-0144)
- Arjen Q. Bakker
- Rob C. Roovers (ORCID: https://orcid.org/0000-0002-9715-2136)
- B. Monica (ORCID: https://orcid.org/0000-0002-2043-7846)
- Esmay Frankin
- Kelly Maijoor
- Surendra Gulla (ORCID: https://orcid.org/0000-0003-1555-2046)
- Michael Koslowski
Institutions
- Atara Biotherapeutics (United States) (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104173
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36